Regulatory Approval for GAPVAC clinical trial for Glioma

Barcelona, 14 October 2014 – GAPCAV Consortium announces today that they are moving a novel concept of fully personalized therapeutic cancer vaccines, Glioma Actively Personalized VAccine Consortium (GAPVAC), into the clinic. The German national authority, the Paul-Ehrlich-Institute (PEI), has approved the start of a phase 1/2 study, GAPVAC-101, which applies for the first time the concept of treating glioblastoma patients based on peptide drugs designed and manufactured for each patient individually according to specific characteristics of their tumor and immune system.GAPVAC Press Release Oct 14